The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia
Abstract
Background: Most cases of hyponatremia – serum sodium concentration ([Na+]) <135 mEq/l (<135 m M) – are associated with an elevated plasma arginine vasopressin level. This study investigated the efficacy and tolerability of intravenous conivaptan (YM087), a vasopressin V 1A/V 2-receptor antagonist, in treating euvolemic and hypervolemic hyponatremia. Methods: Eighty-four hospitalized patients with euvolemic or hypervolemic hyponatremia (serum [Na+] 115 to <130 mEq/l) were randomly assigned to receive intravenous placebo or conivaptan administered as a 30-min, 20-mg loading dose followed by a 96-hour infusion of either 40 or 80 mg/day. The primary efficacy measure was change in serum [Na+], measured by the baseline-adjusted area under the [Na+]-time curve. The secondary measures included time from first dose to a confirmed ≧4 mEq/l serum [Na+] increase, total time patients had serum [Na+] ≧4 mEq/l higher than baseline, change in serum [Na+] from baseline to the end of treatment, and number of patients with a confirmed ≧6 mEq/l increase in serum [Na+] or normal [Na+] (≧135 mEq/l). Results: Both conivaptan doses increased area under the [Na+]-time curve during the 4-day treatment (p < 0.0001 vs. placebo). From baseline to the end of treatment, the least-squares mean ± standard error serum [Na+] increase associated with placebo was 0.8 ± 0.8 mEq/l; with conivaptan 40 mg/day, 6.3 ± 0.7 mEq/l; and with conivaptan 80 mg/day, 9.4 ± 0.8 mEq/l. Conivaptan significantly improved all secondary efficacy measures (p < 0.001 vs. placebo, both doses). Conivaptan was generally well tolerated, although infusion-site reactions led to the withdrawal of 1 (3%) and 4 (15%) of patients given conivaptan 40 and 80 mg/day, respectively. Conclusion: Among patients with euvolemic or hypervolemic hyponatremia, 4-day intravenous infusion of conivaptan 40 mg/day significantly increased serum [Na+] and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Introduction to sample size determination and power analysis for clinical trials
Lachin, J. M. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90001-5 · Cited by 1,012
Cited by
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E., Ichai, C., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3210-2 · Cited by 1,020
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1020 · Cited by 855
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu040 · Cited by 579
Non-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia
Berl, T., Quittnat-Pelletier, F., Verbalis, J. G., Schrier, R. W., Bichet, D. G., Ouyang, J., & Czerwiec, F. S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080857 · Cited by 351
Self-citation
Metadata
- Authors
- Zeltser, D., Rosansky, S., van Rensburg, H., Verbalis, J. G., & Smith, N.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 27
- Issue
- 5
- Pages
- 447-457
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2135149679
- Cited by
- 214
- References
- 1
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.